Language:
Password reminder
No account yet? Register Free
About Us Advertising Info Contact Us Client Login
labmedica.com
Immunology
Features Subscription Partner Sites Journal Info
AB SCIEXVeolia WATERRANDOX LABORATORIES

Biomarkers May Predict Chemo-Resistant Breast Cancers

By Labmedica International staff writers
Posted on 25 Apr 2012


A family of proteins has been identified that could potentially be used as biomarkers to predict resistance to chemotherapy in breast cancer patients.

Protein biomarkers have been identified that are associated with response to neoadjuvant chemotherapy using comparative high-throughput processes based on antibodies and using mass spectrometry, and proteomic analysis of estrogen receptor-positive (ER-positive) breast tumor samples.

Scientists at the University of Hull (UK) conducted comparative proteomic studies using the two dimensional gel electrophoresis, matrix-assisted laser desorption/ionization time-of-flight mass spectrometer (2-DE MALDI TOF/TOF MS) on fresh tumor samples. They identified 132 unique proteins that were significantly differently expressed, more than two-fold, in chemotherapy resistant samples, 57 of which were identified in at least two studies.

Five of the proteins in the 57 candidates belong to the 14-3-3 protein family, namely the isoforms: theta/tau, gamma, epsilon, beta/alpha and zeta/delta, which have previously been associated with chemotherapy resistance in breast cancer. The team says their findings confirm the 14-3-3 protein family as a strong candidate for a predictive test for chemotherapy resistance. Without a means to predict whether chemotherapy will work, some patients with resistant cancers undergo much hardship while suffering the side effects of ineffective chemotherapy options without the benefits, plus they lose valuable time until an effective therapy is found.

The Ultraflex III MALDI TOF/TOF MS used in the study was manufactured by Bruker Daltonics (Billerica, MA, USA). Lynn Cawkwell, PhD, the senior author of the study, said, "If we're correct, we hope that by testing for these proteins, doctors will be able to anticipate a patient's response to different chemotherapies, and decide which course of treatment is most appropriate for them." The team is also investigating radiotherapy resistance in a number of different cancers. The study was published on April 3, 2012, in the Journal of Proteomics.

Related Links:

University of Hull
Bruker Daltonics






HbA1c Analyzer
HbA1c Analyzer
Hematology Analyzer
Hematology Analyzer
Color Slide Printer
Color Slide Printer

More Products

Latest Immunology News

LinkXpress
Click for LinkXpress
Reader Inquiry Service
Enter code to receive information:
Where I can find code?
Featured Whitepaper
SIEMENS DIAGNOSTICS :
Siemens Healthcare Diagnostics Anti-CCP: A Clinical Evaluation Whitepaper

Download Whitepaper
Events
ELA – European Lab Automation congress
06 Jun 2013 - 07 Jun 2013


European Human Genetics Conference 2013
08 Jun 2013 - 11 Jun 2013


8th Forum on Oxidative Stress and Aging
12 Jun 2013 - 14 Jun 2013


More events
GLOBETECH PUBLISHING
Latest Issue

View Digital Edition
Subscribe / Renew
KARL HECHT GMBH & CO KG
DIASOURCE
ALTO MARKETING LIMITED
AACC
BioPorto Diagnostics
GREINER-BIO-ONE
77 ELEKTRONIKA
  labmedica.com Copyright © 2000-2013 Globetech Media. All rights reserved.
Privacy Policy